

Attorney Docket No. 08702.0005-00000
Application No.: 09/816,697

OK TO ENTAIL
M-11/9/04

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions and listings of claims in the application:

1-56. (Canceled)

57. (Previously presented) A method for identifying a compound which inhibits the binding of a SLIC-1 protein to PSGL-1, comprising:

- i) contacting said SLIC-1 protein with a test compound; and
- ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety chosen from:
 - (a) amino acids 1-226 of SEQ ID NO:2;
 - (b) amino acids 1-316 of SEQ ID NO:2; and
 - (c) fragments of (a) or (b) that have PSGL-1 binding activity; and
- 2) optionally, at least one heterologous amino acid sequence.

58. (Previously presented) A method for identifying a compound which increases the binding of a SLIC-1 protein to PSGL-1, comprising:

- i) contacting said SLIC-1 protein with a test compound; and
- ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety chosen from:
 - (a) amino acids 1-226 of SEQ ID NO:2;
 - (b) amino acids 1-316 of SEQ ID NO:2; and

Attorney Docket No. 08702.0005-00000
Application No.: 09/816,697

- (c) fragments of (a) or (b) that have PSGL-1 binding activity; and
- 2) optionally, at least one heterologous amino acid sequence.
59. (Previously presented) The method of claim 57, wherein at least one heterologous sequence is a protein tag.
60. (Previously presented) The method of claim 59, wherein said protein tag is a GST tag.
61. (Previously presented) The method of claim 59, wherein said protein tag is a T7 tag.
62. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2.
63. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2 and a protein tag.
64. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2.
65. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2 and a protein tag.
66. (Currently amended) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids ~~4-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.
67. (Currently amended) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids ~~4-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
68. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

Attorney Docket No. 08702.0005-00000
Application No.: 09/816,697

69. (Previously presented) The method of claim 57, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
70. (Previously presented) The method of claim 58, wherein at least one heterologous sequence is a protein tag.
71. (Previously presented) The method of claim 70, wherein said protein tag is a GST tag.
72. (Previously presented) The method of claim 70, wherein said protein tag is a T7 tag.
73. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2.
74. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-226 of SEQ ID NO:2 and a protein tag.
75. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2.
76. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of amino acids 1-316 of SEQ ID NO:2 and a protein tag.
77. (Currently amended) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-266 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.
78. (Currently amended) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-266 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
79. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

Attorney Docket No. 08702.0005-00000

Application No.: 09/816,697

80. (Previously presented) The method of claim 58, wherein said SLIC-1 protein consists of a fragment of amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
81. (Previously presented) A method for identifying a compound which inhibits the binding of a SLIC-1 protein to PSGL-1, comprising:
- i) contacting said SLIC-1 protein with a test compound; and
 - ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety having PSGL-1 binding activity chosen from:
 - (a) an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2;
 - (b) an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2; and
 - (c) fragments of (a) or (b); and
 - 2) optionally, at least one heterologous amino acid sequence.
82. (Previously presented) A method for identifying a compound which increases the binding of a SLIC-1 protein to PSGL-1, comprising:
- i) contacting said SLIC-1 protein with a test compound; and
 - ii) determining the effect of the test compound on the binding of said SLIC-1 protein to PSGL-1;

wherein said SLIC-1 protein consists of:

- 1) a SLIC-1 moiety having PSGL-1 binding activity chosen from:
 - (a) an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2;

Attorney Docket No. 08702:0005-00000
Application No.: 09/816,697

- (b) an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2; and
 - (c) fragments of (a) or (b); and
 - 2) optionally, at least one heterologous amino acid sequence.
83. (Previously presented) The method of claim 81, wherein at least one heterologous sequence is a protein tag.
84. (Previously presented) The method of claim 83, wherein said protein tag is a GST tag.
85. (Previously presented) The method of claim 83, wherein said protein tag is a T7 tag.
86. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2.
87. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2 and a protein tag.
88. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2.
89. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2 and a protein tag.
90. (Currently amended) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids ~~1-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.

Attorney Docket No. 08702.0005-00000
Application No.: 09/816,697

91. (Currently amended) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 4-266 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
92. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.
93. (Previously presented) The method of claim 81, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
94. (Previously presented) The method of claim 82, wherein at least one heterologous sequence is a protein tag.
95. (Previously presented) The method of claim 94, wherein said protein tag is a GST tag.
96. (Previously presented) The method of claim 94, wherein said protein tag is a T7 tag.
97. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2.
98. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-226 of SEQ ID NO:2 and a protein tag.
99. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2.

Attorney Docket No. 08702.0005-00000

Application No.: 09/816,697

100. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2 and a protein tag.
101. (Currently amended) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids ~~4-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.
102. (Currently amended) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids ~~4-266~~ 1-226 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.
103. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity.
104. (Previously presented) The method of claim 82, wherein said SLIC-1 protein consists of a fragment of an amino acid sequence at least 95% identical to amino acids 1-316 of SEQ ID NO:2, wherein said fragment has PSGL-1 binding activity, and a protein tag.